Solid Biosciences Inc. and Phlox Therapeutics announced a strategic collaboration focused on genetic cardiac diseases. The research collaboration will target a severe form of genetic dilated cardiomyopathy (DCM) for which there is currently a significant unmet need for effective treatments. The strategic collaboration will integrate Solid Biosciences' vector biology, manufacturing capabilities and drug development experience with Phlox's deep expertise in genetic cardiomyopathies and RNA therapeutics.

The companies will collaborate to develop novel precision genetic medicines for this form of DCM. The strategic research collaboration will also be supported in part by a grant from the Dutch Top Sector Life Sciences and Health, a coalition that fosters public-private research and development partnerships that aim to develop innovative healthcare products and services.